title: Ovarian cancer, version 2.2013.
abstract: These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.
authors.affiliation: From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5UCSF Helen Diller Family Comprehensive Cancer Center; 6he Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 7Vanderbilt-Ingram Cancer Center; 8The University of Texas MD Anderson Cancer Center; 9University of Washington/Seattle Cancer Care Alliance; 10Moffitt Cancer Center; 11Duke Cancer Institute; 12University of Michigan Comprehensive Cancer Center; 13Roswell Park Cancer Institute; 14Dana-Farber/Brigham and Women's Cancer Center; 15Massachusetts General Hospital Cancer Center; 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 17Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 18Memorial Sloan-Kettering Cancer Center; 19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 21Stanford Cancer Institute; 22Huntsman Cancer Institute at the University of Utah; and 23National Comprehensive Cancer Network.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Morgan
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
authors.forename: Deborah K
authors.initials: DK
authors.lastname: Armstrong
authors.forename: Robert A
authors.initials: RA
authors.lastname: Burger
authors.forename: Lee-may
authors.initials: LM
authors.lastname: Chen
authors.forename: Larry
authors.initials: L
authors.lastname: Copeland
authors.forename: Marta Ann
authors.initials: MA
authors.lastname: Crispens
authors.forename: David M
authors.initials: DM
authors.lastname: Gershenson
authors.forename: Heidi J
authors.initials: HJ
authors.lastname: Gray
authors.forename: Ardeshir
authors.initials: A
authors.lastname: Hakam
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Havrilesky
authors.forename: Carolyn
authors.initials: C
authors.lastname: Johnston
authors.forename: Shashikant
authors.initials: S
authors.lastname: Lele
authors.forename: Lainie
authors.initials: L
authors.lastname: Martin
authors.forename: Ursula A
authors.initials: UA
authors.lastname: Matulonis
authors.forename: David M
authors.initials: DM
authors.lastname: O'Malley
authors.forename: Richard T
authors.initials: RT
authors.lastname: Penson
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Powell
authors.forename: Steven W
authors.initials: SW
authors.lastname: Remmenga
authors.forename: Paul
authors.initials: P
authors.lastname: Sabbatini
authors.forename: Joseph T
authors.initials: JT
authors.lastname: Santoso
authors.forename: Julian C
authors.initials: JC
authors.lastname: Schink
authors.forename: Nelson
authors.initials: N
authors.lastname: Teng
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Werner
authors.forename: Mary A
authors.initials: MA
authors.lastname: Dwyer
authors.forename: Miranda
authors.initials: M
authors.lastname: Hughes
mesh_terms: D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D012008:Recurrence